Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapeOX, Bevacizumab, and Tislelizumab for Locally Recurrent Colorectal Cancer
NCT06881537Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Objective Response Rate at 15 weeks, R0 Resection Rate at 15 weeks and 3 more. Started Jun 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06881537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881537.